QIAGEN

Name: QIAGEN
Address: Qiagen Str. 1, Hilden, 40724, DE
Telephone: +492103290
Price range: ££

Anrufen Wegbeschreibung Website Service kontaktieren

QIAGEN is the leading provider of sample to insight solutions. Everyone has the right to express their own opinion
• Respecting the rights of others

2.

Links to websites are provided for convenience and do not imply sponsorship, affiliation or endorsement. Guidelines when using our page

We ask that you please adhere to the following guidelines when using our page:

1. Netiquette

Posting and commenting on our page should follow these general communications rules:

• Treating all other users as you would like to be treated by them
• Respecting the opinions of others and not trying to force your opinion on anyone else. Deletion of posts/comments and blocking Facebook accounts

The following actions are examples that are seen as violations of the terms of use. These actions will result in the immediate deletion of posts/comments or, in the case of gross or repeated violations, we will block the user so that he or she is not able to post further content or comments on our page:

• Personal insults or degrading comments of any kind
• Defamatory, anti-constitutional, racist, or pornographic statements or illustrations
• Disparaging comments about institutions, organizations or companies, sexist or racist comments, or hate propaganda
• Any violation of the rights of third parties, in particular copyrights
• Comments that do not relate to the messages under discussion or that are off-topic
• Attacking others or calling for violence of any kind
• Calls to join in demonstrations or rallies of any political orientation
• Offering goods or services, of either a commercial or private nature, or using this page as an advertising space
• Spam, i.e., any form of automatically generated content or repeatedly posting the same comment

3. Privacy policy

We created this page in order to connect and facilitate with interested people an exchange about science, biotechnology, healthcare, molecular diagnostics, and other QIAGEN-related topics. The Privacy Policy covers how we handle personal data, which is submitted to Facebook by clicking the “Like” button on our page. This data is also accessible to QIAGEN. The data we receive from Facebook contains:

• Age demographics
• Place of residence (country and city)
• Gender
• Language
• Activity statistics/rate of all people using our page

Facebook provides this data exclusively in a summarized form. QIAGEN does not receive data on individuals or small user groups. We don’t share the data with third parties. User data is used exclusively to administer our page and to learn more about which topics are of interest to our followers so that we can further improve our page’s offering.

4. Disclaimer

The messages posted in response to our articles reflect the opinions of individual members only. We are not liable for the content of any messages, or for conclusions that may be drawn from such messages. QIAGEN makes no representations or warranties of any kind about the accuracy or completeness of the content.

21/10/2026

QIAGEN has announced an agreement to be acquired by EQT Private Equity through an all-cash public takeover offer at €46.50 per share.

EQT shares our view of QIAGEN’s long-term potential and brings deep healthcare and life sciences experience. Its sector knowledge, global network and operational capabilities make it a strong fit for QIAGEN’s next phase of growth.

Under private ownership, QIAGEN would have greater flexibility to invest for the long term, build on its technologies and pursue the opportunities that matter most to customers.

What drives us every day does not change: Making Improvements in Life Possible.

The agreement follows a comprehensive review of QIAGEN’s strategic options. Our Supervisory Board and Managing Board believe the transaction provides the right environment for QIAGEN’s next growth phase and intend to unanimously recommend acceptance of the offer.

Closing is currently expected in mid-2027, subject to customary regulatory and other conditions. Until closing, QIAGEN will continue to operate as an independent company.

Learn more ➡ https://tinyurl.com/46rkdju4

15/10/2026

Gen Z or millennial, the protocol doesn’t care🫶

Same bench, same QIAGEN.

Tag the one in your lab👇

15/10/2026

Not so long ago, liquid biopsy seemed like science fiction. But in less than two decades, this non-invasive diagnostic approach has become part of everyday practice – and demand is growing so quickly that labs are finding it hard to keep up.

Since its introduction in 2011, non-invasive, blood-based prenatal testing has become one of the fastest-growing genetic tests worldwide. Rather than relying on invasive tests like amniocentesis, prenatal genetic tests can be performed using a simple blood draw from an expectant mother. As a result, prenatal screening is now far more accessible to more people.

But making screening more accessible creates a different challenge for laboratories: how do you process growing numbers of samples efficiently and reliably?

For Jean-Martin Billard and his team at the Institute of Pathology and Genetics in Belgium, meeting this growing demand – and testing around 20,000 blood samples a year – means finding ways to work more efficiently while maintaining analytical performance.

Learn how the Institute of Pathology and Genetics in Belgium is able to process around one-sixth of Belgium’s total annual NIPT activity using QIAsymphony instruments ➡️ https://tinyurl.com/yppf4see

12/10/2026

Bloodstream infections don’t wait. Neither should answers.

The QIAstat-Dx BCID Plus AMR Panels are now available, bringing broad coverage of gram-positive bacteria and fungi (GPF) or gram-negative bacteria (GN) and AMR markers to the QIAstat-Dx platform.

When a blood culture flags positive, time starts ticking. The QIAstat-Dx BCID Plus AMR Panels help deliver timely results in about one hour.

Together, the two complementary panels help laboratories:

✅ Broaden the diagnostic picture: Detect 33 clinically relevant pathogen targets across gram-positive bacteria, fungi and gram-negative bacteria.

✅ Identify potential resistance mechanisms earlier: Detect 28 AMR markers to add crucial resistance information alongside pathogen identification.

✅ Help inform diagnosis and support subsequent clinical decision-making, antimicrobial stewardship and infection-control efforts.

Explore the QIAstat-Dx BCID Plus AMR Panels: https://tinyurl.com/3uwe4sbf

07/10/2026

In science, a fast AI answer is only as good as the evidence behind it. IPA Investigator and the QIAGEN Discovery Platform keep that evidence visible. Learn more ➡ https://tinyurl.com/bde394js

We are introducing new AI capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. They build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights, whose bioinformatics solutions are used by around 150,000 users.

✅ IPA Investigator lets scientists ask questions about their data in natural language and can recommend analyses and carry them out within QIAGEN Ingenuity Pathway Analysis (IPA)

✅ The QIAGEN Discovery Platform combines AI with our biomedical knowledge base and molecular data to help researchers identify potential drug targets and biomarkers, generate hypotheses and automate parts of the discovery process

Both launches are part of a broader rollout of AI across QIAGEN Digital Insights, including AI-powered translation in QIAGEN Clinical Insight (QCI) Interpret and machine learning combined with expert-reviewed information in Franklin by QIAGEN.

06/10/2026

We asked what percentage of people with infection will develop active TB disease during their lifetime without preventive treatment.

The answer? About 5–10%.

Knowing facts like these helps us identify those most at risk and improve patient outcomes. That's why, for over a decade, the Global TB Summit has brought together TB experts, healthcare professionals and advocates from around the world to learn, share and collaborate.

Join us this October to hear from 35+ leading TB experts, hear inspiring TB survivor stories, explore the latest advances in TB management and earn CPD and CME credits.

Secure your spot now ➡️ https://tinyurl.com/43h4w7sr

06/10/2026

When meningitis or encephalitis is suspected, every decision matters.

This World Meningitis Day, join our international panel of clinical and laboratory professionals for a virtual roundtable on syndromic meningitis/encephalitis testing in practice.

Through real-world cases, clinical-impact evidence and a live Q&A, the discussion will explore considerations that follow rapid pathogen detection.

You will learn about:

✅ Supporting clinical pathways, outbreak preparedness and antimicrobial stewardship

✅ Guiding patient selection using clinical suspicion, age, immune status, and local or institutional protocols

✅ Approaching HSV, VZV, HHV-6, unexpected findings, and negative results in high-suspicion cases

Register now ➡️ https://tinyurl.com/mr2apecc

05/10/2026

The 2026 Nobel Prize in Physiology or Medicine highlights how scientific discovery is laying the foundation for a new era in neuroscience.

We congratulate Karl Deisseroth from the Howard Hughes Medical Institute (HHMI) and Stanford University, Peter Hegemann from Humboldt-Universität zu Berlin (Humboldt University of Berlin) and Georg Nagel from the University of Würzburg on receiving this year's award for their discoveries concerning light-gated ion channels and optogenetics, a method that makes it possible to show how nerve cells shape memories, feelings and behaviors in the living brain.

Congratulations to our QIAGEN customers for this tremendous achievement!

Illustration credit: Ill. Niklas Elmehed © Nobel Prize Outreach

29/09/2026

What if we could end TB, together?
Join us at the Global TB Summit 2026, a movement toward making that future possible.

💬Hear powerful stories from TB survivors
🧪Learn from global TB medical experts
🤝Connect with policymakers and passionate advocates
🎓Earn CPD & CME credits along the way

Together, we can fight tuberculosis and move toward a future without TB. 💛
So, are you in? Comment TB SUMMIT and we’ll send you the link.

29/09/2026

Our QIAstat-Dx bloodstream infection portfolio is now complete in the U.S. with FDA clearance of the QIAstat-Dx BCID GN Plus AMR Panel. Learn more ➡ https://tinyurl.com/bhzmeuaf

Bloodstream infections can trigger sepsis, a life-threatening response to infection. According to the U.S. Centers for Disease Control and Prevention, about 1.7 million adults in the U.S. develop sepsis each year, and at least 350,000 die during hospitalization or are discharged to hospice. The new panel complements the recently cleared QIAstat-Dx BCID GPF Plus AMR Panel for gram-positive bacteria and fungi.

✅ The QIAstat-Dx BCID GN Plus AMR Panel identifies 13 gram-negative bacterial pathogen targets and 18 antimicrobial resistance markers in about one hour

✅ Together, the two panels cover 33 pathogen targets and 28 antimicrobial resistance markers, which can provide clinicians with timely information to support treatment decisions

✅ The clearance also expands the QIAstat-Dx infectious disease menu in the U.S., which already covers respiratory, gastrointestinal and meningitis/encephalitis testing

QIAstat-Dx is available in more than 100 countries, with more than 5,200 cumulative placements as of the end of 2025.

Adresse

Qiagen Str. 1
Hilden
40724

Telefon

+492103290

Website

http://www.qiagen.com/

Benachrichtigungen

Erfahren Sie als Erste/r von Neuigkeiten und Aktionen: Wir schicken Ihnen eine E-Mail, wenn QIAGEN etwas veröffentlicht. Ihre E-Mail-Adresse wird für keinen anderen Zweck verwendet, und Sie können sich jederzeit abmelden.